Cardiology Discovery
Because LR3 maintains receptor activity while improving availability in human-relevant systems, its widely studied 7 in human cell culture models to enhance proliferation and survival, providing a translational platform to understand recovery pathways with higher signal through the IGF-1R axis
The dual GIP/GLP-1 action produces stronger and earlier appetite suppression for most patients
including semaglutide branded as Wegovy or Ozempic, and tirzepatide (dual GIP/GLP-1 receptor agonist) branded as Zepbound or Mounjaro, for the management of obesity, type 2 diabetes, and other metabolic conditions increases, so too does the need to assess the advantages and potential downsides of long-term use
CMS will be providing more information in June 2026
A new commentary published in Diabetes, Obesity and Metabolism shares practical recommendations for gathering real world evidence on the use of GLP-1 medications in people with Prader-Willi syndrome